Therapeutic Inertia & Risk Burden in Type 2 Diabetes
Professor Sanjoy Paul
+61 3 9342 8772
With funding support from Novo Nordisk, Prof. Paul is leading a research project to evaluate the therapeutic inertia and risk burden in patients with type 2 diabetes. These studies are based on primary care and ambulatory care large population level databases from UK and USA.
The initial findings have already gained international attention, with the first study reporting the consequences of delay in intensification of treatment for glycaemic control on cardiovascular risk recently published in Cardiovascular Diabetology (2015, 14:100; 3715 accesses since published online in August 2015). His interview during EASD conference on this study can be seen in here.
Prof Sanjoy Paul, Director
Grants from Amylin Pharmaceuticals LLC, and AstraZeneca, USA
Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovascular Diabetology. 2015;14:100.